GenSci048

DRUG3 trials

Sponsors

Changchun GeneScience Pharmaceutical Co., Ltd.

Conditions

Endometriosis-related PainRheumatoid Arthritis Associated Interstitial Lung Disease (RA-ILD)Systemic Sclerosis Associated Interstitial Lung DiseaseSystemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)Uveitis

Phase 2

A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease

RecruitingNCT06189495

Changchun GeneScience Pharmaceutical Co., Ltd.Rheumatoid Arthritis Associated Interstitial Lung Disease (RA-ILD), Systemic Sclerosis Associated Interstitial Lung Disease, Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)

Start: 2023-12-30End: 2026-10-31Target: 30Updated: 2025-01-17

A Phase IIa Clinical Study to Assess the Efficacy and Safety of GenSci048 in Patients With Moderate to Severe Endometriosis-Associated Pain

RecruitingNCT06963177

Changchun GeneScience Pharmaceutical Co., Ltd.Endometriosis-related Pain

Start: 2025-05-26End: 2030-01-06Target: 200Updated: 2025-08-12

A Study of Efficacy and Safety of GenSci048 in Subjects With Active Uveitis.

RecruitingNCT07547995

Changchun GeneScience Pharmaceutical Co., Ltd.Uveitis

Start: 2026-06-29End: 2028-01-13Target: 74Updated: 2026-07-24